Shahrokh F. Shariat
Semmelweis University(HU)Al-Ahliyya Amman University(JO)University of Jordan(JO)University of Copenhagen(DK)Tabriz University of Medical Sciences(IR)Sechenov University(RU)GTx (United States)(US)Shiraz University of Medical Sciences(IR)Cornell University(US)Charles University(CZ)Jordan Hospital(JO)European Association of Urology(NL)Namazi Hospital(IR)United States University(US)Vienna General Hospital(AT)Rigshospitalet(DK)University Medical Center Utrecht(NL)Sorbonne Université(FR)Comprehensive Cancer Center Vienna(AT)Presbyterian Hospital(US)Assistance Publique – Hôpitaux de Paris(FR)Biologie Labor(CH)Universitätsklinikum Krems(AT)Pitié-Salpêtrière Hospital(FR)Austrian Society of Dermatology and Venereology(AT)Reproduktionsmedizin München(DE)Universitätszahnklinik Wien(AT)Institute for Reproductive Health(US)Karl Landsteiner Society(AT)Southwestern Medical CenterOnco-Urologie PrédictiveMedical University of Vienna(AT)The University of Texas Southwestern Medical Center(US)The University of Texas Southwestern Medical Center(US)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Prostate Cancer Diagnosis and Treatment, Prostate Cancer Treatment and Research, Urological Disorders and Treatments
Most-Cited Works
- → EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016(2016)2,277 cited
- → Epidemiology and Risk Factors of Urothelial Bladder Cancer(2012)2,154 cited
- → European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)(2021)1,541 cited
- → European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update(2015)1,341 cited
- → European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update(2019)1,294 cited
- → EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013(2013)1,170 cited